Significantly, results observed in RAS-mutant versus WT human cancer cell lines, were recapitulated upon SHOC2 inactivation in isogenic NL20 immortalized, nontumorigenic human bronchial epithelial cells (Fig. 3e, f), as well as in MEFs derived from Shoc2fl/fl;CreERT2 mice (Fig. 3g), where SHOC2 ablation selectively sensitized cells to the MEKi Selumetinib (but not upon PanRAFi LY3009120) only upon ectopic expression of KRASG12V. This evidence concerns the gene SHOC2 and cancer.